PedAM

Pediatric Disease Annotations & Medicines

Disease	congestive heart failure
Phenotype	C0027051\|myocardial infarct
Sentences	13
PubMedID- 23341788	Pulmonary comorbidity was defined as a history of or ongoing chronic obstructive pulmonary disease, pulmonary tuberculosis, or a forced expiratory volume in 1 second of ≤1.5 l. cardiovascular comorbidity was defined as the presence of one or more of the following conditions: congestive heart failure, ischemic cardiopathy with or without myocardial infarction, severe valvular cardiopathy, and arrhythmia requiring chronic treatment.
PubMedID- 22474044	Postmortem examination revealed coronary arteriosclerosis and myocardial infarction leading to congestive heart failure.
PubMedID- 22977447	The secondary end point included non-cardiac death, cardiac death, myocardial infarction, development of congestive heart failure, and re-hospitalization.
PubMedID- 22357361	Introduction and objectives: to compare acute myocardial infarction patients with or without congestive heart failure in the french fast-mi registry.
PubMedID- 23404303	The end point of this study was the occurrence of maces, which included, as previously described (14,16), cad death, sudden death, nonfatal myocardial infarction, death due to congestive heart failure, unstable angina, need for repeat revascularization (aside from restenosis), stroke or transient ischemic attack, and symptomatic pad documented by angiography.
PubMedID- 21092295	It has been recently reported that postinfarcted filling function decrease was an independent risk factor of congestive heart failure and death in patients with myocardial infarction [13,14].
PubMedID- 23133676	Based on our results we assume that the reported increased mortality is rather a consequence of the concomitant heart disease than the conduction delay in itself as β-ar blockade basically shows positive effects on mortality in patients after myocardial infarction or in patients with congestive heart failure [48], [49].
PubMedID- 23986716	Similar, albeit less dramatic, results have been reported for data obtained from healthy subjects and in patients following myocardial infarction or with congestive heart disease (kleiger et al., 1987; van hoogenhuyze et al., 1991; fleiss et al., 1992).
PubMedID- 21828948	Relationship between plasma homocysteine levels and congestive heart failure in patients with acute myocardial infarction.
PubMedID- 20730062	A meta-analysis of all randomized trials showed that amiodarone reduced total mortality by 10 to 19%.30 the risk reduction was similar in primary prevention after myocardial infarction or in patients with congestive heart failure (chf), and in secondary prevention after cardiac arrest.30 in a pooled database from 2 similar randomized clinical trials (the european amiodarone myocardial infarction trial (emiat) and the canadian amiodarone myocardial infarction trial (camiat)), that evaluated use of amiodarone in primary prevention in patients recovering from myocardial infarction, cardiac death and arrhythmic death or resuscitated cardiac arrest, were significantly lower in patients receiving amiodarone, compared to placebo (p = 0.05 and 0.03, respectively), if they were also receiving beta-blockers.31 there appeared to be no benefit of amiodarone over placebo in patients not receiving beta-blockers.
PubMedID- 23505492	Importantly, in some studies, the definition of incident cvd included congestive heart failure together with myocardial infarction, angina pectoris and cerebrovascular events [3], [41].
PubMedID- 25822937	Cardiovascular deaths were defined as sudden cardiac death, fatal myocardial infarction, death due to congestive heart failure, death immediately after intervention to treat cad, fatal stroke, and other causes of deaths due to cardiac disease.
PubMedID- 21545710	Background: progressive remodeling of the left ventricle (lv) following myocardial infarction (mi) can lead to congestive heart failure, but the underlying initiation factors remain poorly defined.

Page: 1